Additionally, the negative association of ED-A+ Fn serum levels and SMWD as a well-established parameter of functional performance recommended in current PH guidelines could be an impetus for the further evaluation of the molecule as a therapy surveillance marker, especially in PH group 1 (PAH) patients receiving a specific therapy [7]. This evidence concerns the gene EDA and pulmonary arterial hypertension.